Alzheimer's disease progression model using disability assessment for dementia scores from bapineuzumab trials.

ABSTRACT:

Objective

Disability assessment for dementia (DAD) measurements from two phase-3 studies of bapineuzumab in APOE ε4 noncarrier and carrier Alzheimer's disease (AD) patients were integrated to develop a disease progression model.

Methods

We evaluated longitudinal changes in DAD scores, baseline factors affecting disease progression, and bapineuzumab effect on disease progression.

Results

A beta regression model best described DAD disease progression. The estimated treatment effect of bapineuzumab was not significant, consistent with lack of clinical efficacy observed in the primary analysis. The model suggested that progression of DAD tended to decrease with increase in bapineuzumab exposure. The exposure-response relationship was similar regardless of APOE</

SUBMITTER: Xu SX 

PROVIDER: S-EPMC5975025 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature